Cargando…

Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma

HDAC inhibitors (HDACis) have been intensively studied for their roles and potential as drug targets in T-cell lymphomas and other hematologic malignancies. Bisthianostat is a novel bisthiazole-based pan-HDACi evolved from natural HDACi largazole. Here, we report the preclinical study of bisthianost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yu-bo, Zhang, Yang-ming, Huang, Hong-hui, Shen, Li-jing, Han, Xiao-feng, Hu, Xiao-bei, Yu, Song-da, Gao, An-hui, Sheng, Li, Su, Ming-bo, Wei, Xiao-li, Zhang, Yue, Zhang, Yi-fan, Gao, Zhi-wei, Chen, Xiao-yan, Nan, Fa-jun, Li, Jia, Hou, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976035/ https://www.ncbi.nlm.nih.gov/pubmed/34341512 http://dx.doi.org/10.1038/s41401-021-00728-y

Ejemplares similares

Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta-analysis of clinical trials
por: Gao, Xiao, et al.
Publicado: (2019)

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
por: Redic, Kimberly A, et al.
Publicado: (2016)

Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
por: Zheng, Yanhua, et al.
Publicado: (2018)

Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms
por: Ma, Yanping, et al.
Publicado: (2017)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
por: Lin, MaoFang, et al.
Publicado: (2014)

Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins
por: Zhang, Juan, et al.
Publicado: (2021)

Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
por: Gao, Xiaohui, et al.
Publicado: (2023)

Inhibition of Histone Deacetylases Attenuates Morphine Tolerance and Restores MOR Expression in the DRG of BCP Rats
por: He, Xiao-Tao, et al.
Publicado: (2018)

Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis
por: Jiang, Li-Ping, et al.
Publicado: (2022)

Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
por: Luo, Xian-Wu, et al.
Publicado: (2018)

Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner
por: Yuan, Xiang-Gui, et al.
Publicado: (2019)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase 2 is involved in µ-opioid receptor suppression in the spinal dorsal horn in a rat model of chronic pancreatitis pain
por: Liao, Yong-Hui, et al.
Publicado: (2018)

Dysregulation of Histone Acetyltransferases and Deacetylases in Cardiovascular Diseases
por: Wang, Yonggang, et al.
Publicado: (2014)

Histone deacetylase inhibitor givinostat alleviates liver fibrosis by regulating hepatic stellate cell activation
por: Huang, He-Ming, et al.
Publicado: (2021)

Diversity, evolution and expression profiles of histone acetyltransferases and deacetylases in oomycetes
por: Wang, Xiao-Wen, et al.
Publicado: (2016)

Suppression of histone deacetylases by SAHA relieves bone cancer pain in rats via inhibiting activation of glial cells in spinal dorsal horn and dorsal root ganglia
por: He, Xiao-Tao, et al.
Publicado: (2020)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
por: Li, Chunrui, et al.
Publicado: (2021)

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials
por: Huang, Zeng-Yi, et al.
Publicado: (2023)

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
por: Ruan, Min, et al.
Publicado: (2021)

Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy
por: Ke, Xiangyu, et al.
Publicado: (2021)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
por: Pratz, Keith W., et al.
Publicado: (2010)

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
por: Li, Wei, et al.
Publicado: (2023)

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon, Nidhi, et al.
Publicado: (2016)

Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
por: Okabe, Seiichi, et al.
Publicado: (2021)

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

Class I histone deacetylase complex: Structure and functional correlates
por: Wang, Xiao, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

SCARECROW-LIKE15 interacts with HISTONE DEACETYLASE19 and is essential for repressing the seed maturation programme
por: Gao, Ming-Jun, et al.
Publicado: (2015)

The role of class IIa histone deacetylases in regulating endothelial function
por: Shen, Zexu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i1rqkuim8ul2v4b91koa00a5mo